Grace Therapeutics (GRCE) Competitors $2.31 +0.03 (+1.32%) As of 12:34 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrendsBuy This Stock GRCE vs. ATOS, ZURA, ACOG, CLYM, CRBU, HLVX, IVVD, ADAG, BDRX, and SLSShould you be buying Grace Therapeutics stock or one of its competitors? The main competitors of Grace Therapeutics include Atossa Therapeutics (ATOS), Zura Bio (ZURA), Alpha Cognition (ACOG), Climb Bio (CLYM), Caribou Biosciences (CRBU), HilleVax (HLVX), Invivyd (IVVD), Adagene (ADAG), Biodexa Pharmaceuticals (BDRX), and SELLAS Life Sciences Group (SLS). These companies are all part of the "pharmaceutical products" industry. Grace Therapeutics vs. Atossa Therapeutics Zura Bio Alpha Cognition Climb Bio Caribou Biosciences HilleVax Invivyd Adagene Biodexa Pharmaceuticals SELLAS Life Sciences Group Grace Therapeutics (NASDAQ:GRCE) and Atossa Therapeutics (NASDAQ:ATOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation. Does the MarketBeat Community favor GRCE or ATOS? Atossa Therapeutics received 241 more outperform votes than Grace Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Grace Therapeutics an outperform vote while only 65.41% of users gave Atossa Therapeutics an outperform vote. CompanyUnderperformOutperformGrace TherapeuticsOutperform Votes1100.00% Underperform VotesNo VotesAtossa TherapeuticsOutperform Votes24265.41% Underperform Votes12834.59% Does the media prefer GRCE or ATOS? In the previous week, Atossa Therapeutics had 20 more articles in the media than Grace Therapeutics. MarketBeat recorded 21 mentions for Atossa Therapeutics and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.90 beat Atossa Therapeutics' score of 0.60 indicating that Grace Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Grace Therapeutics Very Positive Atossa Therapeutics Positive Do insiders and institutionals believe in GRCE or ATOS? 6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 12.7% of Atossa Therapeutics shares are owned by institutional investors. 13.5% of Grace Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Atossa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer GRCE or ATOS? Grace Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 426.32%. Atossa Therapeutics has a consensus target price of $7.00, indicating a potential upside of 940.27%. Given Atossa Therapeutics' higher possible upside, analysts clearly believe Atossa Therapeutics is more favorable than Grace Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Atossa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, GRCE or ATOS? Atossa Therapeutics is trading at a lower price-to-earnings ratio than Grace Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrace TherapeuticsN/AN/A-$12.85M-$1.16-1.97Atossa TherapeuticsN/AN/A-$30.09M-$0.21-3.20 Which has more risk and volatility, GRCE or ATOS? Grace Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Atossa Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Is GRCE or ATOS more profitable? Grace Therapeutics' return on equity of -20.10% beat Atossa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Grace TherapeuticsN/A -20.10% -17.10% Atossa Therapeutics N/A -35.74%-33.51% SummaryGrace Therapeutics and Atossa Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Remove Ads Get Grace Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRCE vs. The Competition Export to ExcelMetricGrace TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.12M$6.89B$5.63B$7.79BDividend YieldN/A2.81%5.37%4.04%P/E Ratio-1.977.4223.6218.68Price / SalesN/A207.04371.6689.80Price / CashN/A65.6738.1734.64Price / Book0.446.206.734.12Net Income-$12.85M$142.11M$3.20B$247.10M7 Day Performance-10.94%-7.28%-5.32%-3.82%1 Month Performance-24.75%-10.45%-0.39%-6.61%1 Year PerformanceN/A-12.86%7.89%-1.67% Grace Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRCEGrace Therapeutics2.4206 of 5 stars$2.31+1.3%$12.00+419.5%N/A$23.42MN/A-1.99N/APositive NewsGap UpATOSAtossa Therapeutics1.8889 of 5 stars$0.74+2.5%$7.00+841.7%-62.6%$93.51MN/A-3.388Earnings ReportZURAZura Bio2.1505 of 5 stars$1.42+6.8%$15.80+1,012.7%-49.8%$92.72MN/A0.003Earnings ReportACOGAlpha Cognition1.906 of 5 stars$5.70-1.7%$20.00+250.9%N/A$91.31MN/A-2.23N/AEarnings ReportUpcoming EarningsAnalyst ForecastNews CoverageGap UpCLYMClimb Bio2.9977 of 5 stars$1.35+2.3%$10.00+640.7%N/A$88.74MN/A-0.639Earnings ReportGap DownCRBUCaribou Biosciences3.0645 of 5 stars$0.95+0.1%$10.33+986.7%-82.2%$88.44M$9.99M-0.58100Short Interest ↓Gap UpHLVXHilleVax2.5296 of 5 stars$1.75+1.7%$3.00+71.4%-91.3%$87.16MN/A-0.5620Earnings ReportUpcoming EarningsAnalyst ForecastNews CoverageIVVDInvivyd3.3385 of 5 stars$0.72-10.6%$7.89+995.5%-86.4%$86.12M$11.56M-0.37100Short Interest ↓ADAGAdagene2.3292 of 5 stars$1.82+0.6%$8.00+339.6%-45.2%$85.74M$815,746.000.00260BDRXBiodexa Pharmaceuticals0.4071 of 5 stars$2.34+15.8%N/AN/A$85.51M$83,000.000.0020Short Interest ↑High Trading VolumeSLSSELLAS Life Sciences Group0.386 of 5 stars$1.21+12.0%N/A+6.9%$85.16M$1M-1.7510 Remove Ads Related Companies and Tools Related Companies Atossa Therapeutics Alternatives Zura Bio Alternatives Alpha Cognition Alternatives Climb Bio Alternatives Caribou Biosciences Alternatives HilleVax Alternatives Invivyd Alternatives Adagene Alternatives Biodexa Pharmaceuticals Alternatives SELLAS Life Sciences Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRCE) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored“Massive Financial Reset Is Coming”The U.S. markets will see a massive reset, beginning days from now. But the "reset" isn't what you might ex...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grace Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grace Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GRCE Stock Free GRCE Stock Alerts